Healthcare
Rockwell Medical, Inc.(RMTI)
Live Price
Offline$0.62
+0.00% today
1Y Change
-26.44%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $30.00M
- Revenue Growth
- -31.8%
- EPS Growth
- -495.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rockwell Medical, Inc. (RMTI) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $0.62 and down 26.4% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -31.8%, EPS growth of -495.2%, a dividend yield of 0.0%. What stands out right now is revenue -31.8%, EPS -495.2%, free cash flow -137.6% with operating margin -6.8% and ROIC -9.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RMTI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-31.8% vs +7.6% peer median
Operating Margin
Below sector median
-6.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -31.8% and EPS is at -495.2%, with operating margin around -6.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +0.0% | -7.1% | -17.9% |
2026 Mar 26, 2026 | -125.0% | -7.4% | +2.1% | -7.4% |
2025 Nov 12, 2025 | -25.0% | -5.2% | -10.4% | -1.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RMTI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RMTI Max Drawdown
-66.12%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RMTI and SPY.
Company Overview
Rockwell Medical, Inc.
NASDAQ Capital Market
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
- Leadership
- Mark Strobeck
- IPO Date
- Jan 27, 1998
- Employees
- 244
- Street Address
- 30142 South Wixom road
- Mailing
- Wixom, MI, 48393
- Region
- Wixom, MI, US
- Reporting Currency
- USD
- Investor Line
- 248 960 9009
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 9983.8
- Price/Sales
- 0.5
- Price/Book
- 0.9
Growth
- Revenue
- -31.8%
- EPS
- -495.2%
- Free Cash Flow
- -137.6%
Profitability
- Gross Margin
- 16.9%
- Operating Margin
- -6.8%
- Net Margin
- -7.7%
- ROE
- -15.6%
- ROIC
- -9.5%
Balance Sheet
- Debt/Equity
- 0.34
- Current Ratio
- 3.98
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.